{
    "clinical_study": {
        "@rank": "97592", 
        "acronym": "Auto-HBO", 
        "arm_group": {
            "arm_group_label": "Hyperbaric Oxygen Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Administration of hyperbaric oxygen on the morning of stem cell transplant (Day 0)."
        }, 
        "brief_summary": {
            "textblock": "By doing this study, researchers hope to learn the following:\n\n        -  The safety of hyperbaric oxygen administration in the setting of the autologous\n           transplant\n\n        -  The effects of hyperbaric oxygen administration on neutrophil count recovery and\n           engraftment"
        }, 
        "brief_title": "Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multiple Myeloma", 
            "Hodgkin's Disease", 
            "Non-Hodgkin's Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The post stem cell transplant complications of neutropenic fever and mucositis, related to\n      the chemotherapy and/or radiation on hematopoietic tissue administered prior to peripheral\n      blood stem cell transplant, are reversible upon neutrophil count recovery.  The\n      investigators will investigate the use of hyperbaric oxygen as an intervention to shorten\n      neutropenia post-high-dose chemotherapy and autologous peripheral blood stem cell\n      transplant.  The idea of using hyperbaric oxygen therapy in autologous stem cell\n      transplantation is based on the investigators pre-clinical work that supported the use of\n      hyperbaric oxygen to improve umbilical cord blood (cluster of differentiation 34) CD34+ stem\n      cell transplantation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Voluntary written informed consent\n\n          -  Subjects with Multiple Myeloma (MM), Hodgkin's Disease (HD), and non-Hodgkins\n             lymphoma (NHL) who are eligible for high-dose chemotherapy and autologous PBSC\n             transplant.  Subjects should be enrolled within 30 days of transplant.\n\n          -  Subjects must be >/= 18 yrs old and </= 70 yrs old\n\n          -  Karnofsky performance status of >/= 70%\n\n          -  Adequate hepatic, renal, cardiac and pulmonary function to be eligible for\n             transplant.  Minimum criteria include:\n\n               -  ALT (alanine aminotransferase), AST (aspartate aminotransferase): < 4x IULN\n                  (institutional upper limit of normal)\n\n               -  Total bilirubin:  </= 2.0 mg/dL\n\n               -  Creatinine: </= 2.0 mg/dL\n\n               -  EF (ejection fraction) measured by 2D-ECHO or MUGA (multiple gated acquisition)\n                  scan of >/= 45%\n\n               -  FEV1 (forced expiratory volume), FVC (forced vital capacity) and DLCD(diffusing\n                  capacity of lung for carbon monoxide) >/= 50% of predicted value (corrected to\n                  serum hemoglobin)\n\n          -  Women of child-bearing potential and men with partners of child-bearing potential\n             must use adequate contraception prior to study entry and up to 30 days following\n             treatment.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast feeding\n\n          -  Severe chronic obstructive pulmonary disease requiring oxygen supplementation\n\n          -  History of spontaneous pneumothorax\n\n          -  Active ear/sinus infection\n\n          -  Claustrophobia\n\n          -  HIstory of sinus or ear surgery, excluding myringotomy or ear tubes\n\n          -  History of seizures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087657", 
            "org_study_id": "Auto-HBO"
        }, 
        "intervention": {
            "arm_group_label": "Hyperbaric Oxygen Treatment", 
            "description": "Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours", 
            "intervention_name": "Administration of hyperbaric oxygen", 
            "intervention_type": "Device", 
            "other_name": "Monoplace Hyperbaric Chamber Model 3200 and 3200R"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Peripheral Blood Stem Cell (PBSC) Transplant", 
            "Hyperbaric oxygen", 
            "Lymphoma", 
            "Myeloma"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "contact": {
                "email": "oaljitawi@kumc.edu", 
                "last_name": "Omar Aljitawi, MD", 
                "phone": "913-588-6029"
            }, 
            "contact_backup": {
                "email": "kdaniels2@kumc.edu", 
                "last_name": "Kelly Daniels", 
                "phone": "913-945-6591"
            }, 
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66160"
                }, 
                "name": "University of Kansas Medical Center"
            }, 
            "investigator": {
                "last_name": "Omar Aljitawi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplant", 
        "other_outcome": [
            {
                "description": "Statistical methods will be applied to determine if the mean erythropoietin levels during the first 24 hours and 48 hours correlate with time to neutrophil recovery and engraftment.", 
                "measure": "Explore the effects of hyperbaric oxygen (HBO) therapy on erythropoietin (EPO) levels.", 
                "safety_issue": "No", 
                "time_frame": "Assessment at:  Day -7 (lymphoma) or Day -3 (myeloma), Pre-HBO (Day 0), Pre-transplant (6-10hrs post-HBO), 24 and 48 hrs after starting hyperbaric oxygen treatment as well as 3 days post-neutrophil engraftment"
            }, 
            {
                "description": "Erythropoietin blood levels will be correlated to the daily neutrophil counts to assess any relationship between erythropoietin levels and subsequent engraftment and neutrophil recovery.", 
                "measure": "Examine correlation between change to erythropoietin (EPO) levels and time to neutrophil recovery and engraftment.", 
                "safety_issue": "No", 
                "time_frame": "EPO measurments:  Pre-HBO (Day 0), 6-10hrs post-HBO, 24hrs and 48hrs post HBO, as well as 3 days post neutrophil engraftment."
            }
        ], 
        "overall_contact": {
            "email": "oaljitawi@Kumc.edu", 
            "last_name": "Omar Aljitawi, MD", 
            "phone": "913-588-6029"
        }, 
        "overall_contact_backup": {
            "email": "kdaniels2@kumc.edu", 
            "last_name": "Kelly Daniels", 
            "phone": "913-945-6591"
        }, 
        "overall_official": {
            "affiliation": "University of Kansas", 
            "last_name": "Omar Aljitawi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treatment limiting toxicities are defined as the occurrence of any of the following complications within 24hrs of treatment:  seizure disorder, pneumothorax, death, irreversible grade III or any grade IV toxicity that is determined by the treating physician to be at least likely related to HBO therapy.", 
            "measure": "Presence or absence of a treatment limiting toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Toxicity assessment occurs within 24hrs of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087657"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Subjects will be followed daily until neutrophil recovery, defined as three consecutive days of achieving a neutrophil count of > 500/mm3.  If subjects do not exhibit neutrophil recovery by Day 40 post transplant, they will be considered primary graft failures.", 
            "measure": "Reduction in time to neutrophil recovery and engraftment post-cord blood transplant.", 
            "safety_issue": "No", 
            "time_frame": "Daily measurement of neutrophil counts, up to 40 days post transplant."
        }, 
        "source": "University of Kansas", 
        "sponsors": {
            "collaborator": {
                "agency": "Southwest Oncology Group", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Kansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}